University of Minnesota. Driven to Discover.
The shorter, simpler regimen with the new drug is poised to improve treatment against a difficult disease and to lower costs.
As has been the case, California, Florida, New York, and Texas reported half of all TB cases.
Though incidence is down, treatment success for resistant strains is low.
Short-course therapy led to a favorable outcome in 79% of patients, compared with 80% in long-course patients.
Safety profile was good, and sensitivity analysis favored delamanid as part of MDR-TB treatment.
Whole-genome sequencing could lead to faster, more accurate resistance testing.
TB remains high in many low- and middle-income nations, and about 558,000 people in 2017 developed rifampicin-resistant TB.
Newer and repurposed drugs produced better results and fewer deaths than older treatments did.
The changes prioritize newer medications and oral regimens over injectable drugs.
"Our results justify consideration for revised recommendations from WHO and wider use of bedaquiline," the authors write.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.